# Khavinson short peptides: Bronchogen, Cardiogen and seven more

Source: https://aminodesk.com/library/khavinson-bioregulators
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

This page covers nine Russian short peptides that are each sold for a single organ: Bronchogen, Cardiogen, Chonluten, Crystagen, Livagen, Ovagen, Pancragen, Prostamax and Testagen. They belong to the family known as Khavinson bioregulators. We found no controlled human trial of any of the nine, and none has a lawful route in the US.

- **Legal lane:** not FDA-approved. Not eligible for pharmacy compounding. Sold as research chemicals.
- **Evidence grade:** D for each of the nine
- **What they are:** synthetic peptides two to four amino acids long
- **Established human dose:** none

## What they are

Beginning in the 1970s, Vladimir Khavinson's group in St. Petersburg extracted peptide mixtures from animal organs, then made short synthetic peptides meant to reproduce each extract's effect. The idea is that every organ makes its own short regulatory peptides, and that supplying them restores that organ. The synthetic versions are what research suppliers sell.

Members of the family with more of a record have their own pages: [Epitalon](https://aminodesk.com/library/epitalon), [Pinealon](https://aminodesk.com/library/pinealon), [Vilon](https://aminodesk.com/library/vilon), [Cortagen](https://aminodesk.com/library/cortagen), [Cartalax](https://aminodesk.com/library/cartalax) and [Vesugen](https://aminodesk.com/library/vesugen), and the registered Russian drugs [Thymalin](https://aminodesk.com/library/thymalin) and [Thymogen](https://aminodesk.com/library/thymogen).

## The nine on this page

| Peptide | Sold for | Human trial evidence |
| --- | --- | --- |
| **Bronchogen** | Bronchial and lung support. | None found. |
| **Cardiogen** | Heart support. | None found. |
| **Chonluten** | Lung and airway support. Also spelled Choluten. | None found. |
| **Crystagen** | Immune support. | None found. |
| **Livagen** | Liver support and anti-aging. | None found. |
| **Ovagen** | Liver and digestive support. | None found. |
| **Pancragen** | Pancreas and blood sugar support. | None found. |
| **Prostamax** | Prostate support. | None found. |
| **Testagen** | Testicular and hormone support. | None found. |

The target organ in each case is the seller's and developer's description. It is not a tested medical use.

## What the evidence shows

We found no controlled human trial of any of these nine peptides in the sources we reviewed.

For the family as a whole, the record is cell experiments, rodent studies, and small, often unblinded human studies run by the original group. Key findings have not been reproduced by independent teams. The most-cited human study, a 266-person cohort followed for six to eight years, tested thymus and pineal extracts, not these peptides, and was not blinded.

A result in a cell dish shows a possible pathway. It is the kind of evidence furthest from showing that a compound does anything in a living person.

## Legal status

- None of the nine is FDA-approved for any use.
- None is eligible for pharmacy compounding, according to the research summary we read.
- None is among the six peptides in the October 2026 policy. Epitalon, a relative, is.
- What is sold online is a research chemical.

## Reported dosing

**We do not publish a protocol for these compounds.**

No dose has been established in a controlled human trial for any of them. The course schedules that circulate come from the developers' own tradition and from sellers.

## Safety

- No independent human safety data exists for any of the nine.
- Peptides this small are often assumed to be harmless. That assumption has not been tested.
- Each is sold for an organ that, if it is causing symptoms, needs a diagnosis. A research chemical is not a substitute for one.
- Products sold as research chemicals have no verified contents or sterility.

## Common questions

### What are Khavinson bioregulators?

A family of short peptides developed in Russia, each marketed for a particular organ.

### Are Bronchogen, Cardiogen or the others FDA-approved?

No. None of the nine is approved, and none is eligible for pharmacy compounding.

### Have these peptides been tested in people?

We found no controlled human trial of any of the nine. The family's evidence is cell and animal work and small unblinded studies from its developers.

### Which bioregulator has the most evidence?

Epitalon is the most studied of the short peptides. Thymalin and Thymogen are registered drugs in Russia.

## Sources

- [Overview of the Khavinson short peptides and the tiers of evidence behind them](https://ipsnews.net/business/?p=248484)
- [The Peptide Column: bioregulator research summary and legal status](https://the-peptide-column.pages.dev/bioregulators)
- [Khavinson and Morozov, 2003: the 266-person elderly cohort (PubMed)](https://pubmed.ncbi.nlm.nih.gov/14523363/)
- [MedicalResearch.com: what four decades of bioregulator research does and does not show](https://medicalresearch.com/?p=75499)
- [Paper (St. Petersburg), 2024: Khavinson's drugs and their critics in evidence-based medicine](https://papernews.online/en/he-promised-to-extend-the-lives/)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
